Valerio Therapeutics and Abivax target next-generation therapies for inflammatory disease

Valerio Therapeutics SA, listed on Euronext Growth Paris under the ticker ALVIO, has entered a binding term sheet with Abivax SA for an exclusive worldwide research and development collaboration in immune-mediated inflammatory diseases. The companies plan to identify, design, manufacture and evaluate next-generation therapeutic candidates by combining Abivax’s immunology expertise with Valerio’s targeted technology platforms. Valerio could receive an upfront payment of up to approximately €2.4 million, followed by development and commercial milestones, royalties and sublicensing income if a definitive agreement is signed and programmes advance. The announcement positions Valerio alongside a credible partner and creates the prospect of material non-dilutive funding as it rebuilds around preclinical RNA and in vivo cell-therapy assets. The central tension is that the market is valuing platform potential rapidly, while the collaboration’s final terms, targets and development candidates remain to be established.

What does the binding term sheet between Valerio Therapeutics and Abivax actually cover?

The agreement is broader than a single-asset licence but less advanced than a completed partnership. The companies intend to generate, manufacture and test candidates that Abivax may later develop. The disclosure does not identify targets, indications, programme count or development-cost allocation.

A binding term sheet establishes the commercial framework and signals serious intent, but the planned co-ownership and licence agreement has not yet been executed. The upfront payment of up to approximately €2.4 million remains subject to the definitive agreement and applicable conditions. Milestone amounts, royalty rates, sublicensing shares and candidate-selection mechanics were not disclosed.

For Valerio, the strategic benefit is validation from a substantially larger biotechnology company with late-stage ambitions in inflammatory disease. For Abivax, the arrangement creates discovery options without an acquisition. The economic asymmetry is clear: €2.4 million could be significant to Valerio but is modest for Abivax.

Why could the €2.4 million upfront matter more to Valerio Therapeutics than the headline suggests?

Valerio ended 2025 with approximately €1.0 million in cash and generated €2.6 million of annual revenue. Operating expenses fell to €4.8 million from €18.3 million as the company restructured. An upfront of up to €2.4 million is potentially equivalent to more than twice the year-end cash balance and close to a full year of revenue.

The amount is not already available. Payment may depend on completing the definitive agreement and satisfying other conditions, so the €2.4 million remains potential funding rather than cash received.

Non-dilutive research income can fund discovery without issuing new shares at every stage. It may also improve negotiating leverage with future partners. Longer-term value will depend on earning milestones and royalties, not simply the initial payment.

The undisclosed economics limit any attempt to value the collaboration. Milestones are normally spread across years and depend on technical, regulatory and commercial events, while royalties matter only if a product reaches the market. The term sheet may strengthen near-term liquidity and validates the partnership model, but most possible value remains contingent.

How does the Abivax collaboration fit Valerio Therapeutics’ in vivo CAR-T and RNA pipeline?

Valerio’s pipeline update shows a company trying to convert platform science into focused development candidates. VTX-001 targets ankylosing spondylitis, while VTX-002 is aimed at IgG4-related disease. Both are in vivo CAR-T programmes designed to deplete pathogenic immune-cell populations inside the patient.

VTX-003 takes a different route in oncology. The programme uses a V-Body oligonucleotide conjugate to deliver small interfering RNA with the aim of reactivating exhausted T cells. Valerio also says its V-Body platform can be combined with RNA payloads and next-generation lipid nanoparticles, giving the company multiple potential delivery configurations.

Management aims to nominate up to two development candidates within 12 to 18 months and move at least one into a first-in-human study within 18 to 24 months. Those deadlines underline how early the portfolio remains. Candidate nomination still requires target validation, construct optimisation, manufacturability, pharmacology and toxicology.

The collaboration may help Valerio prioritise programmes with stronger biological and commercial logic. Abivax can contribute disease knowledge and clinical-development perspective. Valerio still has to demonstrate selective, durable and controllable in vivo effects with a safety profile suitable for chronic immune-mediated conditions.

How would the proposed Etherna acquisition change Valerio Therapeutics’ ability to deliver?

The collaboration arrives after Valerio announced a binding offer to acquire Etherna Immunotherapies NV at a proposed €30 million enterprise value using cash and shares. Etherna would add messenger RNA, customizable lipid nanoparticles and GMP manufacturing infrastructure. Completion could give Valerio a more integrated route from design through delivery and early manufacturing.

However, Etherna is not yet a completed acquisition. The proposal remains subject to final documentation, Belgian foreign-investment clearance, financing and Valerio shareholder approval for the share consideration. Valerio should therefore not be described as already owning Etherna’s assets or capabilities.

The strategic logic is visible. Valerio is seeking to assemble targeting technology, RNA payloads, lipid-nanoparticle delivery, in vivo cell therapy and manufacturing around a partnership-led model. The Abivax term sheet provides a potential development collaborator for part of that stack. Failure to close or integrate Etherna could slow candidate nomination.

Why is Abivax adding early-stage immunology options after obefazimod’s Phase 3 results?

Abivax is approaching the Valerio collaboration from a very different position. Its lead drug obefazimod achieved clinical remission at week 44 in 50.8% of patients on the 25 mg dose and 51.3% on the 50 mg dose in a Phase 3 ulcerative colitis maintenance study, compared with 10.4% for placebo. The efficacy result was strong, although the initial disclosure triggered investor concern about malignancy cases in the high-dose arm that investigators judged unrelated to treatment.

Expanded data released later in June showed malignancy incidence within expected ranges for ulcerative colitis populations. Abivax then raised approximately US$920 million in an upsized equity offering, extending its stated cash runway into the second quarter of 2029 and supporting a potential US launch, subject to regulatory approval.

Abivax is not using the partnership to rescue its lead programme or close an immediate funding gap. It is using a small portion of a strengthened capital base to seed longer-dated immunology options beyond obefazimod. The collaboration is far too early to affect its near-term regulatory or commercial thesis.

For Valerio, association with a company that has generated successful late-stage data and raised substantial capital is strategically useful. For Abivax, candidates can be screened before larger spending is committed. The partnership resembles an option on future innovation, not a near-term pipeline transformation.

What do ALVIO and ABVX share-price moves reveal about current investor expectations?

Valerio shares traded around €0.48 early in the July 16 session, up roughly 6% on the day and within about 10% of the 52-week high of €0.53. The stock had gained approximately 3.8% over five days, 130.8% over one month and 758.1% over one year, with a 52-week range of roughly €0.05 to €0.53. At the intraday reference price, Valerio’s market capitalisation was approximately €240 million.

That performance indicates that investors are already assigning substantial value to the strategic reset and proposed platform expansion. It also raises the proof threshold. A company with €1.0 million of year-end cash and preclinical lead programmes now carries a valuation that assumes more than balance-sheet repair. Sustaining the rerating will require signed agreements, funded research and candidate selection.

Abivax shares were trading around €118 to €119, giving the company a market capitalisation of about €10.35 billion. The shares were down approximately 3.5% over five days but remained up 42.7% over one month and about 1,510% over one year, within a 52-week range of €6.97 to €139. The contrast is instructive: Abivax’s valuation is anchored primarily in a late-stage asset approaching regulatory submission, while Valerio’s recent rise reflects expectations around platform construction and future deal conversion.

These market snapshots were intraday and can change during the session. They nevertheless show why the same collaboration carries different significance for each company. It may be financially material and identity-defining for Valerio, but strategically optional for Abivax.

Which milestones will show whether Valerio Therapeutics is converting validation into clinical value?

The first test is a definitive co-ownership and licence agreement with confirmation of the upfront and clearer economics. The second is disclosure of initial targets and evidence of funded research. The third is nomination of up to two development candidates within 12 to 18 months and progress towards a first-in-human study within 18 to 24 months.

The proposed Etherna acquisition is another dependency. Closing it on financeable terms could strengthen internal delivery and manufacturing. Delays, financing changes or integration problems could complicate the plan behind the recent rerating.

The announcement has improved Valerio’s strategic position by adding a recognised partner, potential non-dilutive cash and a clearer use case for its technologies. What remains unresolved is whether the term sheet becomes a durable licence, whether the science produces developable candidates and whether Valerio can finance multiple platform ambitions without eroding focus. A signed definitive agreement followed by target selection and reproducible preclinical data would strengthen the thesis. Failure to convert the current sequence of proposals into funded programmes and clinical candidates would weaken it.

What are the key takeaways from Valerio Therapeutics’ Abivax collaboration and pipeline update?

• Valerio Therapeutics and Abivax have signed a binding term sheet for an exclusive worldwide research and development collaboration in immune-mediated inflammatory diseases.
• Valerio may receive up to approximately €2.4 million upfront, plus milestones, royalties and sublicensing income, subject to a definitive agreement and future programme progress.
• The potential upfront is financially material relative to Valerio’s €1.0 million cash balance at the end of 2025 and €2.6 million of annual revenue.
• The agreement validates Valerio’s targeted technology platforms, but it does not yet identify targets, candidates or complete licence economics.
• VTX-001 and VTX-002 are preclinical in vivo CAR-T programmes for ankylosing spondylitis and IgG4-related disease, while VTX-003 applies RNA delivery in oncology.
• Valerio aims to nominate up to two development candidates within 12 to 18 months and move at least one programme towards human testing within 18 to 24 months.
• The proposed €30 million Etherna acquisition could add RNA, lipid-nanoparticle and GMP manufacturing capabilities, but the transaction has not yet completed.
• Abivax gains low-cost pipeline optionality beyond obefazimod after strengthening its balance sheet through a roughly US$920 million offering.
• ALVIO’s sharp one-month and one-year gains mean investors are already pricing in substantial progress from Valerio’s strategic reset.
• The decisive proof points are a signed definitive Abivax agreement, funded target selection, candidate nomination and reproducible preclinical data.